Pediatric and Ambulatory Research in Infectious Diseases (PARI)

February 7, 2024 updated by: Association Clinique Thérapeutique Infantile du val de Marne

Real Time Surveillance of Pediatric Infectious Diseases in French Ambulatory Care: PARI Study

Many ambulatory networks are mainly based on diagnoses made by first-line physicians not specifically trained to join the network. Here we aim to set up a surveillance network on pediatric infectious diseases with an investment in teaching with specific trainings of participating pediatricians, increasing in use of point of care tests, and automated data extraction from the computers of the pediatricians.

Study Overview

Status

Recruiting

Conditions

Detailed Description

107 pediatricians among the 1400 members of the French ambulatory pediatric association, AFPA (Association Française de Pédiatrie Ambulatoire) were involved in this survey.To belong to the PARI network, pediatricians have to use the same software, Axi5-Infansoft (developed by CompuGroup Medical, Nanterre, France) for electronic medical record of children. The pediatricians were trained to the use of point of care tests and to the infectious diagnoses (otitis, pharyngitis, varicella, bronchiolitis, influenza, pneumonia, etc..). The study population consisted of all children under 16 years of age from the patient population for which an infectious disease was diagnosed.

Study Type

Observational

Enrollment (Estimated)

400000

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

1 day to 16 years (Child)

Accepts Healthy Volunteers

N/A

Sampling Method

Probability Sample

Study Population

Children under 16 years with infectious disease

Description

Inclusion Criteria:

  • Children under 16 years of age with at least one infectious disease among:
  • pharyngitis
  • otitis
  • pneumonia
  • influenza
  • bronchiolitisz
  • varicella
  • gastroenteritis
  • enterovirus disease
  • bordetella pertussis disease
  • using the same same software, Axi5-Infansoft (developed by CompuGroup Medical, Nanterre, France)

Exclusion Criteria:

  • parental refusal

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Cohort
  • Time Perspectives: Prospective

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Evaluation of the number of infectious diseases
Time Frame: 5 years
proportion of children under 16 years, with infectious disease
5 years

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Evaluation of the use of point of care tests
Time Frame: 5 years
Proportion of use of point of care tests and positivity rate according to the infectious diseases
5 years
Evaluation of the antibiotic treatments
Time Frame: 5 years
Proportion of each antibiotic treatments according to the infectious diseases
5 years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Association Clinique Thérapeutique Infantile du val de Marne

Collaborators

Sanofi
GlaxoSmithKline
Merck Sharp & Dohme LLC
Pfizer
AFPA (Association Française de Pédiatrie Ambulatoire)

Investigators

  • Study Director: Robert Cohen, Association Clinique et Thérapeutique Infantile du Val de Marne

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Helpful Links

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

June 26, 2017

Primary Completion (Estimated)

June 27, 2030

Study Completion (Estimated)

August 2, 2030

Study Registration Dates

First Submitted

July 8, 2020

First Submitted That Met QC Criteria

July 10, 2020

First Posted (Actual)

July 15, 2020

Study Record Updates

Last Update Posted (Actual)

February 8, 2024

Last Update Submitted That Met QC Criteria

February 7, 2024

Last Verified

January 1, 2024

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • ACT0116

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Pneumonia

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Spain

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe